MAPK3 and neoplasm: Sobral et al. demonstrated in vitro and in vivo in head and neck squamous carcinoma (HNSCC) models, that knockdown of SET rescued the activity of PP2A, reduced the levels of phospho -ERK1/2 and phospho -p53(Ser15), impaired cell proliferation, enhanced cell sensitivity to the standard treatment with cisplatin, increased sensitivity to antineoplastic treatments and reduced tumour invasion [70].